Suppliers and packagers for ACYCLOVIR

ACYCLOVIR

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Apotex	ACYCLOVIR	acyclovir	CAPSULE;ORAL	075677	ANDA	Major Pharmaceuticals	0904-5789-61	100 BLISTER PACK in 1 CARTON (0904-5789-61) / 1 CAPSULE in 1 BLISTER PACK	2006-03-20
Apotex	ACYCLOVIR	acyclovir	CAPSULE;ORAL	075677	ANDA	Cardinal Health 107, LLC	55154-7629-0	10 BLISTER PACK in 1 BAG (55154-7629-0) / 1 CAPSULE in 1 BLISTER PACK	2007-04-19
Apotex	ACYCLOVIR	acyclovir	CAPSULE;ORAL	075677	ANDA	Apotex Corp.	60505-0042-6	100 CAPSULE in 1 BOTTLE (60505-0042-6)	2006-03-20
Apotex	ACYCLOVIR	acyclovir	CAPSULE;ORAL	075677	ANDA	American Health Packaging	68084-107-01	100 BLISTER PACK in 1 BOX, UNIT-DOSE (68084-107-01) / 1 CAPSULE in 1 BLISTER PACK (68084-107-11)	2014-02-06
Apotex	ACYCLOVIR	acyclovir	CAPSULE;ORAL	075677	ANDA	Proficient Rx LP	71205-243-30	30 CAPSULE in 1 BOTTLE (71205-243-30)	2006-03-20
Apotex	ACYCLOVIR	acyclovir	CAPSULE;ORAL	075677	ANDA	Proficient Rx LP	71205-243-60	60 CAPSULE in 1 BOTTLE (71205-243-60)	2006-03-20

Acyclovir API Suppliers: Global Landscape and Market Dynamics

Last updated: February 19, 2026

Acyclovir, a synthetic nucleoside analog, is a cornerstone antiviral medication. Its efficacy against herpes simplex viruses (HSV), varicella-zoster virus (VZV), and Epstein-Barr virus (EBV) drives consistent global demand. The supply chain for acyclovir active pharmaceutical ingredient (API) is characterized by a mix of established and emerging manufacturers, primarily concentrated in Asia, with significant players in India and China. Pricing is subject to market competition, regulatory compliance, and raw material availability.

Key Manufacturing Hubs and Dominant Suppliers?

The production of acyclovir API is globalized, with the majority of manufacturing capacity located in India and China. These regions offer cost advantages due to lower labor and operational expenses, coupled with substantial chemical synthesis infrastructure.

Major Acyclovir API Manufacturers

• Hetero Drugs Ltd. (India): A leading global producer of APIs and finished dosage forms. Hetero Drugs has a significant manufacturing footprint and a diverse product portfolio, including antivirals.
• Laurus Labs (India): Known for its strong capabilities in complex chemistry and large-scale API manufacturing. Laurus Labs is a significant supplier of various APIs, including nucleoside analogs.
• Divi's Laboratories (India): A prominent contract manufacturing organization (CMO) and API supplier. Divi's is recognized for its quality standards and large-scale production of key pharmaceutical ingredients.
• Zhejiang NHU Co., Ltd. (China): A major chemical and pharmaceutical company with substantial API production capacity. NHU is a significant player in the global vitamin and API markets.
• Hubei Biocause Pharmaceutical Co., Ltd. (China): Specializes in the production of APIs, including antibiotics and antivirals. Hubei Biocause is an established supplier to the global pharmaceutical industry.

These manufacturers operate under stringent Good Manufacturing Practice (GMP) guidelines, essential for supplying regulated markets like the United States and Europe. Audits by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are critical for market access.

Patent Landscape and Exclusivity?

The original patents for acyclovir have long expired. This has led to a highly competitive generic market. However, secondary patents related to novel formulations, manufacturing processes, or polymorphic forms can still impact market exclusivity and supply dynamics.

Acyclovir Process Patents

While the core molecule is off-patent, companies may hold patents on specific, more efficient, or environmentally friendly synthesis routes. These process patents can offer a competitive advantage by reducing manufacturing costs or improving impurity profiles.

• Example of Process Innovation: Patents might cover specific crystallization methods to achieve a desired polymorphic form of acyclovir, which can affect solubility and bioavailability. The U.S. Patent and Trademark Office (USPTO) and the European Patent Office (EPO) are key repositories for such filings.

Formulation Patents

Patents covering specific drug delivery systems, such as sustained-release formulations or topical applications of acyclovir, can extend market exclusivity for certain products. These patents do not cover the API itself but the final drug product.

• Key Considerations for Formulations:
  • Ophthalmic Suspensions: Patented methods for stabilizing acyclovir in ophthalmic solutions.
  • Topical Creams: Novel excipient combinations that enhance skin penetration.
  • Oral Formulations: Patented coatings or matrix systems for controlled release.

The absence of a dominant molecule patent means that competition among API suppliers is primarily driven by cost, quality, and regulatory compliance.

Regulatory Approvals and Quality Standards?

Access to major pharmaceutical markets, particularly the U.S. and EU, necessitates adherence to strict regulatory requirements. This includes obtaining Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) and filing Drug Master Files (DMFs) with the FDA.

FDA Drug Master Files (DMFs)

A DMF is a submission to the FDA for a pharmaceutical product that allows the agency to review confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.

• Number of Active DMFs for Acyclovir API: A review of FDA databases indicates a substantial number of active DMFs filed by various international manufacturers for acyclovir API, reflecting the broad supplier base. For instance, as of recent data, there are dozens of DMFs active for acyclovir, demonstrating significant global manufacturing engagement. (Source: FDA DMF Database, specific counts fluctuate)

Certificates of Suitability (CEPs)

A CEP is issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). It certifies that the quality of a substance is suitably controlled by the monograph(s) of the European Pharmacopoeia.

• CEP Holders for Acyclovir: Many of the leading Indian and Chinese manufacturers hold CEPs for acyclovir, facilitating its use in pharmaceutical products marketed within the EU. This certification is a critical prerequisite for API suppliers targeting European markets. (Source: EDQM CEP Database)

Good Manufacturing Practices (GMP)

Compliance with GMP is non-negotiable for all API manufacturers supplying regulated markets. This involves rigorous quality control, validated manufacturing processes, and comprehensive documentation.

• GMP Audit Frequency: Regulatory bodies conduct periodic GMP audits to ensure ongoing compliance. Deviations can lead to import alerts or warning letters, disrupting supply chains.

Market Dynamics and Pricing Trends?

The global acyclovir API market is characterized by intense competition, which generally leads to price stability, with fluctuations driven by raw material costs, energy prices, and geopolitical factors.

Pricing Factors

• Raw Material Costs: The cost of key starting materials for acyclovir synthesis, such as guanine and specific chemical reagents, directly impacts API pricing.
• Manufacturing Scale: Larger production volumes typically result in lower per-unit costs due to economies of scale.
• Regulatory Compliance Costs: Investments in GMP compliance, quality control, and DMF/CEP filings contribute to the overall cost of production.
• Geopolitical Stability: Disruptions in key manufacturing regions or global shipping lanes can lead to temporary price increases.

Competitive Landscape

The market is largely driven by generic manufacturers. The primary competitive differentiator among API suppliers is the balance of cost, consistent quality, and reliable supply chain management.

• Volume vs. Price: While some smaller manufacturers may compete on slightly lower prices for specific regional markets, the major global suppliers focus on large-volume contracts with pharmaceutical companies, ensuring consistent supply and quality at competitive rates.

Emerging Trends and Future Outlook?

The acyclovir market, while mature, is influenced by evolving regulatory expectations and the continuous drive for manufacturing efficiency.

Focus on Impurity Profiling

Regulatory agencies are increasingly scrutinizing API impurity profiles. Manufacturers are investing in advanced analytical techniques to identify and control process-related impurities and degradants.

• ICH Guidelines: Adherence to International Council for Harmonisation (ICH) guidelines, particularly ICH Q3A (Impurities in New Drug Substances) and ICH Q3B (Impurities in New Drug Products), is paramount.

Supply Chain Resilience

Recent global events have highlighted the importance of supply chain resilience. Pharmaceutical companies are diversifying their supplier base and seeking greater transparency from API manufacturers.

• Dual Sourcing Strategies: Many drug manufacturers are adopting dual-sourcing strategies for critical APIs like acyclovir to mitigate risks associated with single-supplier dependencies.

Green Chemistry Initiatives

There is a growing interest in developing more sustainable and environmentally friendly manufacturing processes for APIs. This includes reducing solvent usage, minimizing waste generation, and improving energy efficiency.

• Process Optimization: Research into catalytic methods or continuous flow chemistry for acyclovir synthesis could lead to more sustainable production in the future.

Key Takeaways

• Acyclovir API manufacturing is dominated by companies in India and China, driven by cost advantages and established chemical synthesis capabilities.
• The patent landscape for acyclovir is characterized by expired molecule patents, making the market highly competitive for generic producers.
• Regulatory compliance, evidenced by FDA DMFs and EDQM CEPs, is critical for market access in developed countries.
• API pricing is influenced by raw material costs, manufacturing scale, and regulatory adherence, with a generally competitive global market.
• Future trends focus on enhanced impurity control, supply chain resilience, and the adoption of greener manufacturing processes.

Frequently Asked Questions

1. What are the primary countries for acyclovir API production? India and China are the leading global producers of acyclovir API.

2. Are there any active patents on the acyclovir molecule itself? No, the primary patents covering the acyclovir molecule have long expired, making it a widely available generic drug substance.

3. What is the significance of a DMF for an acyclovir API supplier? A Drug Master File (DMF) submitted to the U.S. Food and Drug Administration (FDA) allows the agency to review confidential details of the API manufacturing process, facilities, and quality controls, which is essential for pharmaceutical companies seeking to use the API in their drug products approved in the U.S.

4. How does GMP compliance affect acyclovir API pricing? Adherence to Good Manufacturing Practices (GMP) involves significant investment in quality control systems, validated processes, and documentation. These compliance costs are factored into the overall pricing of the acyclovir API.

5. What are the main factors driving price fluctuations for acyclovir API? Price fluctuations are primarily driven by the cost of raw materials, energy prices, global demand, and any disruptions in the manufacturing or logistics supply chain.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website - Specific URL for DMF search tools or policy documents]

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from [EDQM Website - Specific URL for CEP search or information]

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website - Specific URL for ICH Q3A and Q3B guidelines]